Kurma Partners
Edit

Kurma Partners

https://www.kurmapartners.com
Last activity: 01.10.2025
Active
Invests in categories: MedtechHealthTechTechnologyBioTechDevelopmentHardwareDrugDataResearchProduct
Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).
Portfolio
58
Persons
22
Mentions
50
Location: France, Ile-de-France
Employees: 11-50
Founded date: 2009
Investment Type: Venture Capital
Investment Stage: Series B; Series C

Portfolio 58

DateNameWebsiteTotal RaisedLocation
11.07.2025NUCLIDIUM ...nuclidium.com$101.75MSwitzerlan...
07.07.2025EvlaBioevlabio.com$24.62MSwitzerlan...
30.10.2023Shorla Onc...shorlaoncology.com$43.3MIreland
30.10.2023Sunrisehellosunrise.com$13.34MBelgium, N...
30.10.2023Poppinspoppins.io$18.88MFrance, Il...
30.10.2023Raidiumraidium.eu-France, Il...
30.10.2023Axithraaxithra.com$10.7M-
30.10.2023ARMGO Phar...armgo.com$35MUnited Sta...
30.10.2023NaoX Techn...naox-technologies.com-France, Il...
30.10.2023Corteria P...corteriapharma.com$69.6MFrance, Il...
Show more

Persons 22

DateFirst NameLast NameTitleLinkedInLocation
-Amanda Get...-Partnerlinkedin.c...-
-Séverine P...-Investor R...linkedin.c...-
-Alain Horv...-Partnerlinkedin.c...-
-Fatima Bou...-Assistante...-
-Théo Espos...-Financial ...linkedin.c...-
-Laura Acha...-Associatelinkedin.c...-
-Jean-Franç...-Partnerlinkedin.c...-
-Steffi Min...-Office Man...linkedin.c...-
-Muriel Dom...-Legal Mana...linkedin.c...-
-Hadrien Bo...-Principallinkedin.c...-
Show more

Mentions in press and media 50

DateTitleDescription
01.10.2025Sunrise Group: $29 Million Raised For Expanding Dreem HealthSunrise Group, known as a leader in sleep health technology, has announced a funding round of $29 million dedicated to expanding Dreem Health, its innovative digital sleep clinic, to ensure its services reach all 50 states in the U.S. This ...
25.09.2025Sunrise Group Raises $29M to Expand Dreem Health and Build the Largest U.S. Sleep ClinicWhat You Should Know: –Sunrise Group, a leader in sleep health technology, today announced a $29 million funding round to expand Dreem Health, its digital sleep clinic, across all 50 states. – The round was led by Eurazeo, with participatio...
12.07.2025Swiss Biotech Secures Major Funding for Advanced Cancer TreatmentsSwiss biotech firm NUCLIDIUM secured €84 million in Series B funding. This significant capital injection propels its proprietary copper-based theranostic platform. The company targets advanced cancer diagnosis and treatment. Funds will acce...
11.07.2025NUCLIDIUM raises €84M Series B to advance copper-based cancer therapiesNUCLIDIUM, a Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer, has raised €84 million Series B funding. Leveraging copper is...
10.07.2025Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancerBasel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising €84 million. The round was led b...
10.07.2025Nuclidium Raises €84M in Series B FundingNuclidium, a Basel, Switzerland-based clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, raised €84M in Series B funding The round was co-led by Angelini Ventures, Kurma Growth Opportuniti...
10.07.2025CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy...
07.07.2025EvlaBio secures €21 million in seed funding Founded with a mission to address high unmet medical need in the cardiorenal field, Swiss German biotech company EvlaBio is developing a targeted treatment for patients suffering from Chronic Kidney Disease (CKD) with limited therapeutic o...
28.05.2025To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B fundingThe Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round. Nuevocor said in a state...
07.05.2025Nuevocor's $45 Million Leap: A New Dawn for Cardiomyopathy TreatmentIn the world of biotechnology, every dollar counts. A recent infusion of $45 million into Nuevocor, a Singapore-based company, is more than just a financial boost. It’s a lifeline for patients grappling with cardiomyopathies, particularly t...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In